The Global Genomic Medicine Collaborative (G2MC) is an action collaborative among global leaders in the implementation of genomic medicine in clinical care. Arising from the 2014 Global Leaders in Genomic Medicine Summit at the US National Academy of Sciences in Washington DC (8-9 January), the purpose of the G2MC is to identify opportunities and foster global collaborations for enabling the demonstration of value and the effective use of genomics in medicine. Engaging multiple stakeholders across the globe, the G2MC group, under the auspices of the Roundtable on Genomics and Precision Health, seeks to improve global health by catalyzing the implementation of genomic tools and knowledge into health care delivery globally. To accomplish these goals, seven working groups were created, including communications, education, evidence, IT/bioinformatics, pharmacogenomics, policy, and a steering group to guide and support efforts among working groups.
Specifically, it is intended to:
- Serve as nexus, clearinghouse, and knowledge base for genomic medicine activities globally;
- Develop opportunities for global genomic medicine demonstration projects (implementation and outcomes research) and;
- Capture and disseminate best practices for genomic medicine (in bioinformatics, education, evidence, pharmacogenomics, policy) across the global genomic medicine community.
The purpose and goals of the Global Genomic Medicine Collaborative are:
- Develop projects with global participation
- Opportunities to disseminate learnings for genomic medicine implementation
- Educational platforms to support genomic medicine projects
- Community engagement and access to global genomic medicine expertise
- Creation of a registry or catalog of genomic medicine projects and programs across the globe to stimulate collaboration and efficiency in translation
- Be a global policy forum for genomic medicine
- Mapping the global genomic medicine landscape particularly as it relates to policy and implementation
- Global eradication of preventable Stevens Johnson Syndrome/Toxic Epidermal Necrolysis